Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Titel:
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy
Auteur:
Patterson, Karl Prabhu, Vimalanand Xu, Ruifeng Li, Haojie Meng, Yang Zarabi, Natalie Zhong, Yichen Batteson, Rachael Pellissier, James Keefe, Stephen Grivas, Petros de Wit, Ronald